Complete searchable index of every FDA and EMA-approved oncology therapy documented across all 50 tumor types on PipelineEvidence. Search the table below, or browse by cancer type.
Select a tumor type to view approved therapies, clinical trials, and pipeline data
Filter by name, tumor type, or drug class
| Brand Name | Generic Name | Drug Class | Tumor Types | FDA Year |
|---|---|---|---|---|
| idecabtagene vicleucel (ide-cel) | Multiple Myeloma | Cell Therapy | — | |
| nab-paclitaxel (albumin-bound paclitaxel) | Pancreatic Cancer | Chemotherapy | — | |
| brentuximab vedotin | Hodgkins Lymphoma • Mycosis Fungoides | ADC | 2011 | |
| everolimus | Breast Cancer • Kidney Cancer • Neuroendocrine Tumors | mTOR Inhibitor | 2012 | |
| niraparib + abiraterone acetate | Prostate Cancer | PARP Inhibitor | 2023 | |
| alectinib | Lung Cancer | ALK Inhibitor | — | |
| pemetrexed | Mesothelioma | Chemotherapy | 2004 | |
| brigatinib | Lung Cancer | ALK Inhibitor | — | |
| lifileucel | Melanoma | Cell Therapy | 2024 | |
| nelarabine | Acute Lymphoblastic Leukemia | Chemotherapy | 2005 | |
| atezolizumab + bevacizumab | Liver Cancer | Checkpoint Inhibitor | — | |
| bevacizumab | Brain Cancer • Cervical Cancer • Colorectal Cancer • Lung Cancer • Mesothelioma • Ovarian Cancer | VEGF/TKI | 2009 | |
| iobenguane i-131 | Pheochromocytoma Paraganglioma | Radiopharmaceutical | — | |
| erdafitinib | Bladder Cancer | Kinase Inhibitor | — | |
| avelumab | Bladder Cancer • Merkel Cell Carcinoma | Checkpoint Inhibitor | — | |
| avelumab + axitinib | Kidney Cancer | Checkpoint Inhibitor | 2019 | |
| cisplatin + etoposide + bleomycin | Testicular Cancer | Chemotherapy | — | |
| inotuzumab ozogamicin | Acute Lymphoblastic Leukemia | ADC | — | |
| zenocutuzumab-zbco | Lung Cancer | Bispecific | — | |
| blinatumomab | Acute Lymphoblastic Leukemia | Bispecific | — | |
| bosutinib | Chronic Myeloid Leukemia | BCR-ABL TKI | — | |
| encorafenib + binimetinib | Colorectal Cancer • Melanoma | BRAF/MEK | 2017 | |
| lisocabtagene maraleucel | Non Hodgkins Lymphoma | Cell Therapy | 2021 | |
| zanubrutinib | Chronic Lymphocytic Leukemia • Mantle Cell Lymphoma • Waldenstrom Macroglobulinemia | BTK Inhibitor | 2023 | |
| cabozantinib | Kidney Cancer • Liver Cancer • Thyroid Cancer | VEGF/TKI | 2021 | |
| liposomal doxorubicin | Kaposi Sarcoma | Chemotherapy | — | |
| acalabrutinib | Chronic Lymphocytic Leukemia • Mantle Cell Lymphoma | BTK Inhibitor | 2019 | |
| vandetanib | Thyroid Cancer | RET/Multi-Kinase | 2011 | |
| carboplatin | Testicular Cancer | Chemotherapy | — | |
| ciltacabtagene autoleucel (cilta-cel) | Multiple Myeloma | Cell Therapy | — | |
| lomustine | Brain Cancer | Chemotherapy | — | |
| lomustine (ccnu) | Brain Cancer | Chemotherapy | 1976 | |
| cisplatin + gemcitabine | Nasopharyngeal Carcinoma | Chemotherapy | — | |
| glofitamab-gxbm | Non Hodgkins Lymphoma | Bispecific | 2023 | |
| cobimetinib | Melanoma | BRAF/MEK | 2015 | |
| cyclophosphamide + vincristine + dacarbazine | Pheochromocytoma Paraganglioma | Chemotherapy | — | |
| ramucirumab | Colorectal Cancer • Gastric Cancer • Liver Cancer • Lung Cancer | VEGF/TKI | 2015 | |
| dabrafenib + trametinib | Melanoma | BRAF/MEK | — | |
| daratumumab | Multiple Myeloma | Anti-CD38/SLAMF7 | — | |
| datopotamab deruxtecan | Lung Cancer | ADC | — | |
| glasdegib | Acute Myeloid Leukemia | Epigenetic/IDH/Other Targeted | 2018 | |
| mirvetuximab soravtansine-gynx | Ovarian Cancer | ADC | — | |
| elranatamab-bcmm | Multiple Myeloma | Bispecific | 2023 | |
| elotuzumab | Multiple Myeloma | Anti-CD38/SLAMF7 | — | |
| telisotuzumab vedotin | Lung Cancer | ADC | — | |
| encorafenib + cetuximab | Colorectal Cancer | BRAF/MEK | — | |
| fam-trastuzumab deruxtecan-nxki (t-dxd) | Breast Cancer | ADC | 2019 | |
| trastuzumab deruxtecan | Breast Cancer • Gastric Cancer | ADC | — | |
| fam-trastuzumab deruxtecan | Lung Cancer | ADC | — | |
| ensartinib | Lung Cancer | ALK Inhibitor | — | |
| epcoritamab | Non Hodgkins Lymphoma | Bispecific | 2023 | |
| cetuximab | Colorectal Cancer • Head Neck Cancer | HER2/EGFR Targeted | — | |
| vismodegib | Basal Cell Carcinoma | Other | — | |
| apalutamide | Prostate Cancer | Hormonal (Prostate) | — | |
| edp-m | Adrenocortical Carcinoma | Chemotherapy | 1970 | |
| 5-fu + leucovorin + irinotecan + oxaliplatin | Pancreatic Cancer | Chemotherapy | — | |
| tivozanib | Kidney Cancer | VEGF/TKI | 2021 | |
| fruquintinib | Colorectal Cancer | VEGF/TKI | 2023 | |
| obinutuzumab | Chronic Lymphocytic Leukemia • Follicular Lymphoma | Anti-CD20 | — | |
| afatinib | Lung Cancer | EGFR Inhibitor | — | |
| imatinib | Chronic Myeloid Leukemia | BCR-ABL TKI | 2001 | |
| carmustine implant | Brain Cancer | Chemotherapy | 1996 | |
| imatinib | Chordoma | BCR-ABL TKI | — | |
| imatinib | Chronic Myeloid Leukemia | BCR-ABL TKI | 2010 | |
| eribulin | Sarcoma | Chemotherapy | — | |
| trastuzumab | Breast Cancer • Esophageal Cancer • Gastric Cancer | HER2/EGFR Targeted | 1998 | |
| zongertinib | Lung Cancer | HER2/EGFR Targeted | — | |
| palbociclib | Breast Cancer | CDK4/6 Inhibitor | 2015 | |
| taletrectinib | Lung Cancer | NTRK/ROS1 | — | |
| ponatinib | Acute Lymphoblastic Leukemia | BCR-ABL TKI | 2012 | |
| enasidenib | Acute Myeloid Leukemia | Epigenetic/IDH/Other Targeted | 2017 | |
| ibrutinib | Chronic Lymphocytic Leukemia • Mantle Cell Lymphoma • Waldenstrom Macroglobulinemia | BTK Inhibitor | — | |
| tarlatamab-dlle | Lung Cancer • Small Cell Lung Cancer | Bispecific | — | |
| durvalumab | Biliary Tract Cancer • Lung Cancer • Small Cell Lung Cancer | Checkpoint Inhibitor | — | |
| durvalumab + tremelimumab-actl | Liver Cancer | Checkpoint Inhibitor | 2022 | |
| talimogene laherparepvec (t-vec) | Melanoma | Immunotherapy (Other) | 2015 | |
| axitinib | Kidney Cancer | VEGF/TKI | — | |
| gefitinib | Lung Cancer | EGFR Inhibitor | — | |
| inavolisib | Breast Cancer | PI3K/AKT | 2024 | |
| pirtobrutinib | Chronic Lymphocytic Leukemia • Mantle Cell Lymphoma | BTK Inhibitor | 2023 | |
| dostarlimab | Endometrial Cancer | Checkpoint Inhibitor | — | |
| cabazitaxel | Prostate Cancer | Chemotherapy | — | |
| ado-trastuzumab emtansine (t-dm1) | Breast Cancer | ADC | 2013 | |
| pembrolizumab | Anal Cancer • Bladder Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Cutaneous Squamous Cell • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Head Neck Cancer • Hodgkins Lymphoma • Liver Cancer • Lung Cancer • Melanoma • Merkel Cell Carcinoma • Penile Cancer • Small Bowel Cancer • Uveal Melanoma • Vulvar Cancer | Checkpoint Inhibitor | — | |
| pembrolizumab + axitinib | Kidney Cancer | Checkpoint Inhibitor | — | |
| pembrolizumab + lenvatinib | Kidney Cancer | Checkpoint Inhibitor | 2021 | |
| tebentafusp | Uveal Melanoma | Bispecific | — | |
| ribociclib | Breast Cancer | CDK4/6 Inhibitor | 2017 | |
| adagrasib | Lung Cancer | KRAS Inhibitor | — | |
| tisagenlecleucel | Acute Lymphoblastic Leukemia • Non Hodgkins Lymphoma | Cell Therapy | — | |
| carfilzomib | Multiple Myeloma | Proteasome Inhibitor | — | |
| lazertinib | Lung Cancer | EGFR Inhibitor | — | |
| lenvatinib + pembrolizumab | Endometrial Cancer | Checkpoint Inhibitor | — | |
| lenvatinib | Liver Cancer • Thyroid Cancer | VEGF/TKI | 2018 | |
| cladribine | Hairy Cell Leukemia | Chemotherapy | — | |
| cemiplimab | Basal Cell Carcinoma • Cutaneous Squamous Cell | Checkpoint Inhibitor | — | |
| cemiplimab-rwlc | Lung Cancer | Checkpoint Inhibitor | — | |
| trifluridine/tipiracil | Colorectal Cancer | Other | 2017 | |
| toripalimab | Nasopharyngeal Carcinoma | Checkpoint Inhibitor | — | |
| lorlatinib | Lung Cancer | ALK Inhibitor | — | |
| sotorasib | Lung Cancer | KRAS Inhibitor | — | |
| moxetumomab pasudotox | Hairy Cell Leukemia | Monoclonal Antibody | — | |
| mosunetuzumab-axgb | Follicular Lymphoma • Non Hodgkins Lymphoma | Bispecific | 2022 | |
| lutetium lu 177 dotatate | Neuroendocrine Tumors | Radiopharmaceutical | — | |
| olaparib | Ovarian Cancer • Pancreatic Cancer • Prostate Cancer | PARP Inhibitor | — | |
| mitotane | Adrenocortical Carcinoma | Chemotherapy | 1970 | |
| futibatinib | Biliary Tract Cancer | Kinase Inhibitor | 2022 | |
| rituximab | Follicular Lymphoma | Anti-CD20 | — | |
| methotrexate + doxorubicin + cisplatin | Osteosarcoma | Chemotherapy | — | |
| margetuximab-cmkb | Breast Cancer | HER2/EGFR Targeted | 2020 | |
| trametinib | Melanoma | BRAF/MEK | — | |
| mifamurtide | Osteosarcoma | Other | — | |
| tafasitamab | Non Hodgkins Lymphoma | Anti-CD20 | — | |
| nivolumab | Kidney Cancer | Checkpoint Inhibitor | — | |
| gemtuzumab ozogamicin | Acute Myeloid Leukemia | ADC | 2017 | |
| nab-paclitaxel + gemcitabine | Pancreatic Cancer | Chemotherapy | — | |
| neratinib | Breast Cancer | HER2/EGFR Targeted | 2017 | |
| sorafenib | Kidney Cancer • Liver Cancer • Thyroid Cancer | VEGF/TKI | — | |
| ixazomib | Multiple Myeloma | Proteasome Inhibitor | — | |
| pentostatin | Hairy Cell Leukemia | Chemotherapy | — | |
| nivolumab + ipilimumab | Kidney Cancer • Mesothelioma | Checkpoint Inhibitor | — | |
| darolutamide | Prostate Cancer | Hormonal (Prostate) | 2013 | |
| sonidegib | Basal Cell Carcinoma | Other | — | |
| irinotecan liposome injection | Pancreatic Cancer | Chemotherapy | — | |
| azacitidine (oral) | Acute Myeloid Leukemia | Chemotherapy | 2020 | |
| nivolumab | Anal Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Head Neck Cancer • Hodgkins Lymphoma • Lung Cancer • Melanoma | Checkpoint Inhibitor | — | |
| nivolumab + cabozantinib | Kidney Cancer | Checkpoint Inhibitor | 2021 | |
| nivolumab + ipilimumab | Kidney Cancer • Melanoma • Mesothelioma | Checkpoint Inhibitor | — | |
| nivolumab + relatlimab-rmbw | Melanoma | Checkpoint Inhibitor | 2022 | |
| tumor treating fields (ttfields) | Brain Cancer | Other | 2015 | |
| relugolix | Prostate Cancer | Hormonal (Prostate) | 2020 | |
| elacestrant | Breast Cancer | Endocrine (SERD) | 2023 | |
| folfox | Small Bowel Cancer | Chemotherapy | — | |
| paclitaxel | Kaposi Sarcoma | Chemotherapy | — | |
| enfortumab vedotin-ejfv | Bladder Cancer | ADC | — | |
| enfortumab vedotin | Bladder Cancer | ADC | — | |
| pemigatinib | Biliary Tract Cancer | Kinase Inhibitor | 2020 | |
| pembrolizumab + axitinib | Kidney Cancer | Checkpoint Inhibitor | — | |
| pertuzumab | Breast Cancer | Monoclonal Antibody | 2012 | |
| alpelisib | Breast Cancer | PI3K/AKT | 2019 | |
| lutetium lu 177 vipivotide tetraxetan | Prostate Cancer | Radiopharmaceutical | 2013 | |
| polatuzumab vedotin | Non Hodgkins Lymphoma | ADC | 2019 | |
| pomalidomide | Multiple Myeloma | IMiD | — | |
| necitumumab | Lung Cancer | HER2/EGFR Targeted | — | |
| mogamulizumab | Mycosis Fungoides | Monoclonal Antibody | — | |
| sipuleucel-t | Prostate Cancer | Cell Therapy | — | |
| repotrectinib | Lung Cancer | NTRK/ROS1 | — | |
| selpercatinib | Lung Cancer • Thyroid Cancer | RET/Multi-Kinase | 2020 | |
| lenalidomide | Follicular Lymphoma • Multiple Myeloma | IMiD | 2019 | |
| revumenib | Acute Myeloid Leukemia | Epigenetic/IDH/Other Targeted | 2024 | |
| olutasidenib | Acute Myeloid Leukemia | Epigenetic/IDH/Other Targeted | 2022 | |
| rituximab | Non Hodgkins Lymphoma | Anti-CD20 | — | |
| entrectinib | Lung Cancer | NTRK/ROS1 | — | |
| rucaparib | Ovarian Cancer • Prostate Cancer | PARP Inhibitor | — | |
| amivantamab-vmjw | Lung Cancer | Bispecific | — | |
| midostaurin | Acute Myeloid Leukemia | Other | 2017 | |
| isatuximab | Multiple Myeloma | Anti-CD38/SLAMF7 | — | |
| lanreotide | Neuroendocrine Tumors | Other | — | |
| dasatinib | Chronic Myeloid Leukemia | BCR-ABL TKI | 2010 | |
| regorafenib | Colorectal Cancer • Liver Cancer | VEGF/TKI | 2017 | |
| sunitinib | Kidney Cancer • Neuroendocrine Tumors | VEGF/TKI | — | |
| capmatinib | Lung Cancer | VEGF/TKI | — | |
| dabrafenib | Melanoma | BRAF/MEK | — | |
| dabrafenib + trametinib | Lung Cancer • Thyroid Cancer | BRAF/MEK | — | |
| osimertinib | Lung Cancer | EGFR Inhibitor | — | |
| talquetamab-tgvs | Multiple Myeloma | Bispecific | 2023 | |
| talazoparib | Prostate Cancer | PARP Inhibitor | 2023 | |
| erlotinib | Lung Cancer | EGFR Inhibitor | — | |
| nilotinib | Chronic Myeloid Leukemia | BCR-ABL TKI | 2010 | |
| tazemetostat | Follicular Lymphoma • Sarcoma | Epigenetic/IDH/Other Targeted | — | |
| brexucabtagene autoleucel | Acute Lymphoblastic Leukemia • Mantle Cell Lymphoma | Cell Therapy | 2021 | |
| atezolizumab | Bladder Cancer • Lung Cancer • Small Cell Lung Cancer | Checkpoint Inhibitor | — | |
| atezolizumab + bevacizumab | Liver Cancer | Checkpoint Inhibitor | 2020 | |
| teclistamab-cqyv | Multiple Myeloma | Bispecific | 2023 | |
| temozolomide | Brain Cancer | Chemotherapy | — | |
| temozolomide | Brain Cancer | Chemotherapy | 2005 | |
| tepotinib | Lung Cancer | VEGF/TKI | — | |
| ivosidenib | Acute Myeloid Leukemia • Biliary Tract Cancer | Epigenetic/IDH/Other Targeted | 2018 | |
| standard chemotherapy | Penile Cancer | Other | — | |
| tisotumab vedotin | Cervical Cancer | ADC | — | |
| topotecan | Small Cell Lung Cancer | Chemotherapy | — | |
| sacituzumab govitecan-hziy | Bladder Cancer • Breast Cancer | ADC | — | |
| sacituzumab govitecan | Breast Cancer | ADC | — | |
| capivasertib | Breast Cancer | PI3K/AKT | 2023 | |
| tucatinib | Breast Cancer | HER2/EGFR Targeted | — | |
| tucatinib + trastuzumab | Colorectal Cancer | HER2/EGFR Targeted | 2023 | |
| lapatinib | Breast Cancer | HER2/EGFR Targeted | 2007 | |
| vincristine + doxorubicin + cyclophosphamide | Ewing Sarcoma | Chemotherapy | — | |
| panitumumab | Colorectal Cancer | HER2/EGFR Targeted | — | |
| bortezomib | Mantle Cell Lymphoma • Multiple Myeloma | Proteasome Inhibitor | — | |
| venetoclax | Acute Myeloid Leukemia • Chronic Lymphocytic Leukemia | BCL-2 Inhibitor | 2018 | |
| abemaciclib | Breast Cancer | CDK4/6 Inhibitor | 2017 | |
| larotrectinib | Lung Cancer | NTRK/ROS1 | — | |
| dacomitinib | Lung Cancer | EGFR Inhibitor | — | |
| vorasidenib | Brain Cancer | Epigenetic/IDH/Other Targeted | 2024 | |
| pazopanib | Sarcoma | VEGF/TKI | — | |
| zolbetuximab-clzb | Gastric Cancer | HER2/EGFR Targeted | 2024 | |
| daunorubicin/cytarabine liposome | Acute Myeloid Leukemia | Chemotherapy | 2017 | |
| belzutifan | Kidney Cancer | Epigenetic/IDH/Other Targeted | 2021 | |
| crizotinib | Lung Cancer | ALK Inhibitor | — | |
| radium ra 223 dichloride | Prostate Cancer | Radiopharmaceutical | 2013 | |
| gilteritinib | Acute Myeloid Leukemia | Kinase Inhibitor | 2018 | |
| selinexor | Multiple Myeloma | XPO1 Inhibitor | 2019 | |
| enzalutamide | Prostate Cancer | Hormonal (Prostate) | — | |
| ipilimumab | Melanoma | Checkpoint Inhibitor | — | |
| axicabtagene ciloleucel (axi-cel) | Non Hodgkins Lymphoma | Cell Therapy | 2017 | |
| axicabtagene ciloleucel | Non Hodgkins Lymphoma | Cell Therapy | — | |
| trabectedin | Sarcoma | Chemotherapy | — | |
| ziv-aflibercept | Colorectal Cancer | VEGF/TKI | — | |
| sunvozertinib | Lung Cancer | EGFR Inhibitor | — | |
| niraparib | Ovarian Cancer | PARP Inhibitor | — | |
| vemurafenib | Melanoma | BRAF/MEK | — | |
| lurbinectedin | Ewing Sarcoma • Lung Cancer • Small Cell Lung Cancer | Chemotherapy | — | |
| ceritinib | Lung Cancer | ALK Inhibitor | — | |
| loncastuximab tesirine-lpyl | Non Hodgkins Lymphoma | ADC | 2021 | |
| retifanlimab | Merkel Cell Carcinoma | Checkpoint Inhibitor | — | |
| abiraterone acetate | Prostate Cancer | Hormonal (Prostate) | — | |
| abiraterone | Prostate Cancer | Hormonal (Prostate) | — | |
| Iclusig | ponatinib | BCR-ABL TKI | Chronic Myeloid Leukemia | 2012 |
| Scemblix | asciminib | BCR-ABL TKI | Chronic Myeloid Leukemia | 2021 |
| Retevmo | selpercatinib | RET/Multi-Kinase | Thyroid Cancer | 2020 |
| Caprelsa | vandetanib | RET/Multi-Kinase | Thyroid Cancer | 2011 |
| Gavreto | pralsetinib | RET/Multi-Kinase | Thyroid Cancer | 2020 |
| Tafinlar + Mekinist | dabrafenib + trametinib | BRAF/MEK | Thyroid Cancer | 2018 |
| Yescarta | axicabtagene ciloleucel | Cell Therapy | Follicular Lymphoma | 2021 |
| Istodax | romidepsin | Epigenetic/IDH/Other Targeted | Mycosis Fungoides | 2009 |
| Zolinza | vorinostat | Epigenetic/IDH/Other Targeted | Mycosis Fungoides | 2006 |
| Enhertu | fam-trastuzumab deruxtecan | ADC | Esophageal Cancer | 2021 |
| Cyramza | ramucirumab | Monoclonal Antibody | Esophageal Cancer | 2014 |
| Xermelo | telotristat ethyl | Other | Neuroendocrine Tumors | 2017 |
| Tazverik | tazemetostat | Epigenetic/IDH/Other Targeted | Sarcoma | 2020 |
| Clolar | clofarabine | Chemotherapy | Acute Lymphoblastic Leukemia | 2004 |
| Rylaze | asparaginase erwinia chrysanthemi | Chemotherapy | Acute Lymphoblastic Leukemia | 2021 |
| Rituxan | rituximab | Anti-CD20 | Waldenstrom Macroglobulinemia | 1997 |